Vidyya Medical News Servicesm
Vidyya, from the Sanskrit "vaidya," a practitioner who has come to understand the science of life.
 |
Vidyya |
|
Ars Medica Home |
|
Vidyya Archives |
|
Search Vidyya |
|
Ex Libris |
|
Subscriptions |
|
About Vidyya |
|
|
|
In Today's Vidyya Hemophilia patients who contracted AIDS in the 80s will begin to see compensation soon. |
|
HHS Begins Notifying Ricky Ray Hemophilia Relief Fund
Recipients Of Payments HHS Secretary Donna E. Shalala announced today that the Department of Health and Human Services began notifying the first eligible families that will receive payments from the Ricky Ray Hemophilia Relief Fund. More... |
|
Additional Prescription Dispensing Errors Involving Lamictal Tablets And Lamisil Tablets Reported Medication dispensing errors are a serious threat to quality health care and necessitate the combined efforts of prescribers, dispensers, manufacturers and patients to minimize their occurrence. Glaxo Wellcome Inc. has received reports of dispensing errors involving Lamictal ® (lamotrigine) Tablets and other prescription drugs; most of these errors have been with the prescription medication Lamisil ® (terbinafine hydrochloride) Tablets, some of which have resulted in serious adverse events. More... |
|
Complete Prescribing Information For Lamictal® (Lamotrigine)
Lamictal is an antiepileptic drug marketed as 25-mg (white), 100-mg (peach), 150-mg (cream), and 200-mg (blue), shield-shaped tablets bearing "Lamictal " and the numeric representation of the strength (e.g., "Lamictal ®150"). Lamictal Chewable Dispersible Tablets are 5mg and 25mg white tablets engraved with "GX CL2" and "GX CL5," respectively. More... |
|
AMA Heads To Oklahoma And Tennessee To Mobilize Support For Patients' Bill Of Rights With a Senate vote on a patients' bill of rights expected in early September, American Medical Association leaders this week head to Oklahoma and Tennessee to mobilize grassroots support to pass a strong patients' bill of rights. More... |
|
Beta Blocking Agent Demonstrates Survival Benefit In Patients With Advanced Heart Failure Landmark study results reported by researchers showed that the beta blocking agent Coreg® (carvedilol) decreased mortality rates by 35 percent in patients with the most advanced stage of heart failure who were already taking standard therapy. Coreg is the first beta blocking agent to show a significant survival benefit in this patient population. These results were presented today at the European Society of Cardiologists (ESC) 22nd Annual Congress in Amsterdam. More... |
Ars Medica Home | Ex Libris | Vidyya |
Subscription Information | About Vidyya | Vidyya Archives |
Editor: Susan K. Boyer, RN
© RAmEx Ars Medica, Inc. All rights reserved.